Tags

Type your tag names separated by a space and hit enter

Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Hepatogastroenterology. 2012 Oct; 59(119):2099-2103.H

Abstract

BACKGROUND/AIMS

To investigate the advantage of Chlorella vulgaris supplementation as an adjunctive therapy in patients with non-alcoholic fatty liver disease (NAFLD).

METHODOLOGY

In a randomized, open-label clinical trial, 76 individuals with NAFLD were randomly assigned to: 1) Chlorella group (n=33), receiving C. vulgaris extract (1200 mg/day) + metformin (750 mg/ day) + vitamin E (200 mg/day) for 3 months, or 2) Metformin group (n=43), receiving metformin (1250 mg/ day) + vitamin E (200 mg/day) for 3 months. Weight, body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) index as well as serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), insulin, total and direct bilirubin, fasting blood sugar (FBS), glycated hemoglobin (HbA1c), uric acid, albumin and lipid profile were evaluated at baseline and at the end of trial.

RESULTS

Weight and BMI were decreased in both groups. Serum ALT, AST, triglycerides, uric acid, HbA1c and HOMA-IR index were reduced only in the Chlorella group whereas significant changes in total cholesterol, LDL, HDL and FBS were only observed in the metformin group. There were also borderline significant reductions in insulin and FBS in the Chlorella group.

CONCLUSIONS

The findings of the present trial indicated that addition of C. vulgaris extract to the therapeutic regimen of NAFLD including metformin and vitamin E, is associated with favorable effects on serum levels of transaminases, triglycerides as well as insulin sensitivity. Therefore, C. vulgaris extract might be a promising hepatoprotective supplement for patients with NAFLD.

Authors+Show Affiliations

Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. yunespanahi@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23234816

Citation

Panahi, Yunes, et al. "Investigation of the Effects of Chlorella Vulgaris Supplementation in Patients With Non-alcoholic Fatty Liver Disease: a Randomized Clinical Trial." Hepato-gastroenterology, vol. 59, no. 119, 2012, pp. 2099-2103.
Panahi Y, Ghamarchehreh ME, Beiraghdar F, et al. Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. Hepatogastroenterology. 2012;59(119):2099-2103.
Panahi, Y., Ghamarchehreh, M. E., Beiraghdar, F., Zare, R., Jalalian, H. R., & Sahebkar, A. (2012). Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. Hepato-gastroenterology, 59(119), 2099-2103. https://doi.org/10.5754/hge10860
Panahi Y, et al. Investigation of the Effects of Chlorella Vulgaris Supplementation in Patients With Non-alcoholic Fatty Liver Disease: a Randomized Clinical Trial. Hepatogastroenterology. 2012;59(119):2099-2103. PubMed PMID: 23234816.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. AU - Panahi,Yunes, AU - Ghamarchehreh,Mohammad Ebrahim, AU - Beiraghdar,Fatemeh, AU - Zare,Rnmarjan, AU - Jalalian,Hamid Reza, AU - Sahebkar,Amirhossein, PY - 2012/12/14/entrez PY - 2012/12/14/pubmed PY - 2013/6/19/medline SP - 2099 EP - 2103 JF - Hepato-gastroenterology JO - Hepatogastroenterology VL - 59 IS - 119 N2 - BACKGROUND/AIMS: To investigate the advantage of Chlorella vulgaris supplementation as an adjunctive therapy in patients with non-alcoholic fatty liver disease (NAFLD). METHODOLOGY: In a randomized, open-label clinical trial, 76 individuals with NAFLD were randomly assigned to: 1) Chlorella group (n=33), receiving C. vulgaris extract (1200 mg/day) + metformin (750 mg/ day) + vitamin E (200 mg/day) for 3 months, or 2) Metformin group (n=43), receiving metformin (1250 mg/ day) + vitamin E (200 mg/day) for 3 months. Weight, body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) index as well as serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), insulin, total and direct bilirubin, fasting blood sugar (FBS), glycated hemoglobin (HbA1c), uric acid, albumin and lipid profile were evaluated at baseline and at the end of trial. RESULTS: Weight and BMI were decreased in both groups. Serum ALT, AST, triglycerides, uric acid, HbA1c and HOMA-IR index were reduced only in the Chlorella group whereas significant changes in total cholesterol, LDL, HDL and FBS were only observed in the metformin group. There were also borderline significant reductions in insulin and FBS in the Chlorella group. CONCLUSIONS: The findings of the present trial indicated that addition of C. vulgaris extract to the therapeutic regimen of NAFLD including metformin and vitamin E, is associated with favorable effects on serum levels of transaminases, triglycerides as well as insulin sensitivity. Therefore, C. vulgaris extract might be a promising hepatoprotective supplement for patients with NAFLD. SN - 0172-6390 UR - https://www.unboundmedicine.com/medline/citation/23234816/Investigation_of_the_effects_of_Chlorella_vulgaris_supplementation_in_patients_with_non_alcoholic_fatty_liver_disease:_a_randomized_clinical_trial_ L2 - http://www.diseaseinfosearch.org/result/4280 DB - PRIME DP - Unbound Medicine ER -